

Commission on Cancer State Chair Town Hall

January 22, 2025



CoC State Chair Town Hall

Maria Castaldi, MD, FACS
Chair
Committee on Cancer Liaison



Quan Ly, MD, FACS
Vice-Chair
Committee on Cancer Liaison



Welcome to New CoC State Chairs



Makesha Miggins, MD, FACS
South Texas State Chair



Jason P. Wilson, MD, MBA, FACS
Virginia State Co-Chair



Victor Zaydfudim, MD, FACS
Virginia State Co-Chair

CoC Update

- Monthly CLP and Accreditation Site Visit List
- Post-Town Hall Communications
- 2025 State Chair Activity Report
- 2025 CoC Research Paper Competition
- Upcoming Meetings:
 - 2025 ACS Cancer Conference: March 12-14 in Phoenix, AZ
 - CoC Fall Meetings: October 4 in Chicago, IL (tentative)

Engaging With Your State Cancer Coalition

Commission on Cancer (CoC) State Chair
Quarterly Town Hall
January 22, 2025

How Were State Cancer Coalitions Established?


- The **Centers for Disease Control and Prevention** established the National Comprehensive Cancer Control Program in 1998
- CDC's NCCCP provides **funds, guidance, and technical assistance** to help cancer control coalitions implement effective and sustainable state/tribal/territorial plans to prevent and control cancer.
 - All 50 states and the District of Columbia.
 - 8 U.S.–associated Pacific islands/territories.
 - 7 tribes and tribal organizations.

Where are state coalitions “housed”?


- Usually run out of a state health department
 - Two fulltime staff
- Yet some state health depts sub-contract part of their grant award to another entity to help run the coalition
 - An existing non-profit or University -- the coalition is just one part of what that organization does
 - Or to a stand alone 501c3 Cancer Coalition, which gets funding from multiple sources
 - Average CDC NCCCP award is around \$350K/state...

Coalitions of Multisector Partners

Of coalitions in the United States...



State Cancer Plans are the driving force behind “Comprehensive Cancer Control”



Every State Cancer Plan is Different

- Common types of cancer in its communities (places where a certain cancer is diagnosed more often than in the rest of the country, state, or territory).
- Things that can lead to cancer in the area (for instance, sun exposure in places that have a lot of sunny days each year, or lack of physical activity in communities without parks and places to walk or bike).



ARIZONA CANCER

CONTROL PLAN 2024-2029

- Letters of support
- Introduction
- Cancer data
- Arizona cancer coalition
- Early detection and prevention
- Treatment
- Survivorship and quality of life
- Policy
- Childhood cancer
- Resources

Objective three: Increase colorectal cancer screening rates among Arizonans who are 45 years of age and older from 54% to 65%.

Strategies

1. Advance health equity by expanding access to care and services through screening and patient navigation in an effort to promote the broad adoption of navigation reimbursement targeting rural and urban communities.
2. Develop an evaluation tool to examine the intersectionality of evidence-based interventions and promising practices.
3. Promote health systems and payer-based interventions such as patient reminders, provider reminders, provider assessment and feedback and actively engage in reducing structural barriers targeting rural and urban communities.

Successes!

- **Cancer Coalitions can....**

- Increase chronic disease coordination – tobacco, nutrition, physical activity, sun safety
- Increase CRC screening rates through campaigns like “80% in Every Community”
- Increase HPV vaccination rates
- Advocate for partners’ collaboration on diagnosis, treatment
- Support and expand cancer survivorship programs
- Focus efforts on long-lasting changes – policies and systems

ACOS CoC is part of a national support system for Cancer Coalitions!

Comprehensive Cancer Control National Partnership (CCCNP)



Why Get Involved as a State Chair?

- Get the big picture of cancer in your state (data, services, reports)
- Get to know others that care about and are implementing cancer efforts in your communities
- Help pass state and local policies
- Be a liaison between the coalition and your state's CLP's and accredited programs
- Increased visibility for your health system
- Learn about resources that could help your facility

American Cancer Society Comprehensive Cancer Control Initiatives

Facilitative Leadership for Cancer Coalitions

14-week Intensive
skill-building
training series for
grantees

Topical Learning Communities

Cancer Planning
CRC Mortality
Disparities

Timely & relevant webinars

Host bi-monthly
webinars on timely
cancer control topics

Resource Development & Promotion

At-A-Glance
Screening Briefs

Roles You Can Play

- Medical advisor
- Coalition leadership
- Workgroup member
- Share clinical perspectives
- Testify to elected officials
- Speaker
- Open doors to system change efforts



First Steps To Take

- Check out your State Cancer Plan <https://www.cdc.gov/comprehensive-cancer-control/about/programs.html>
- Be on the lookout for an email from **Melissa Leeb**, connecting you with you with your state's comprehensive cancer control coalition staff person.
- Reach out to your regional American Cancer Society colleague! <https://acs4ccc.org/acs-ccc-resources/acs-regional-partners/>

Thank you!

Let's hear from your colleagues...



NCDB Data Tools Demonstration

Aaron Bleznak, MD, FACS
Chair, CoC Accreditation Committee

Background with CoC

- Cancer Liaison Physician 20 years
- State Chair, Pennsylvania 3 terms
- Chair, Committee on Cancer Liaison 6 years
- Site Reviewer 14 years
- Chair, Accreditation Committee Current

[Home](#)

[Contact Us](#)

Aaron David Bleznak,
MD, MBA, FACS, FSSO
Riverside Health
System
Company Id: 18470
SAR

[Site Information](#)

[Site Profile](#)

[Site Contacts](#)

[Data Platform Contacts](#)

[Invoice](#)

[Program Enrollment](#)

[Schedule Site Visit](#)

[PRQ](#)

[Networks](#)

[Network & Merger](#)

[Applications](#)

[NCDB Reporting Tools](#)

[Site Visit History](#)

[File Sharing](#)

[Resources](#)

[Surgical Quality Partner](#)

[Marketing Resources](#)



Commission on Cancer
American College of Surgeons

Welcome to the Commission on Cancer Quality Portal.

[Home](#)

[Contact Us](#)

Aaron David Bleznak,
MD, MBA, FACS, FSSO
Riverside Health
System
Company Id: 18470
SAR

[Site Information](#)

[Site Profile](#)

[Site Contacts](#)

[Data Platform Contacts](#)

[Invoice](#)

[Program Enrollment](#)

[Schedule Site Visit](#)

[PRQ](#)

[Networks](#)

[Network & Merger](#)

[Applications](#)

[NCDB Reporting Tools](#)

[Site Visit History](#)

[File Sharing](#)

[Resources](#)

[Surgical Quality Partner](#)

[Marketing Resources](#)



Commission on Cancer
American College of Surgeons



A QUALITY PROGRAM
of the AMERICAN COLLEGE
OF SURGEONS

NCDB Reporting Tools

[Site by Stage Distribution Report](#)

[NCDB: Hospital Comparison Benchmark Reports](#)

[NCDB: Survival Reports \(V2\)](#)

[Cancer Quality Improvement Program \(CQIP\) Reports](#)

[Rapid Cancer Reporting System \(RCRS\)](#)

[Home](#)

[Contact Us](#)

Aaron David Bleznak,
MD, MBA, FACS, FSSO
Riverside Health
System
Company Id: 18470
SAR

[Site Information](#)

[Site Profile](#)

[Site Contacts](#)

[Data Platform Contacts](#)

[Invoice](#)

[Program Enrollment](#)

[Schedule Site Visit](#)

[PRQ](#)

[Networks](#)

[Network & Merger](#)

[Applications](#)

[NCDB Reporting Tools](#)

[Site Visit History](#)

[File Sharing](#)

[Resources](#)

[Surgical Quality Partner](#)

[Marketing Resources](#)



Commission on Cancer
American College of Surgeons



A QUALITY PROGRAM
of the AMERICAN COLLEGE
OF SURGEONS

NCDB Reporting Tools

[Site by Stage Distribution Report](#)

[NCDB: Hospital Comparison Benchmark Reports](#)

[NCDB: Survival Reports \(V2\)](#)

[Cancer Quality Improvement Program \(CQIP\) Reports](#)

[Rapid Cancer Reporting System \(RCRS\)](#)

Sign in to your account

Username

Password

[Forgot password?](#)

[Need help?](#)

[Sign In](#)

Select a view

National Cancer Database

20000690 Riverside Health System -- NT18470

Hospitals -- 10701

Home Page

Welcome,
Aaron Bleznak

Currently Viewing

National Cancer Database
20000690 Riverside Health System –
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Dashboard

CoC Quality Measures

Note: report displays data available for the current year - 2, as well as 2 years of subsequent data.

Primary Site	Measure	2021 PR	2022 PR	2023 PR
Bladder	BLCT1	43.75%	42.86%	30.00%
Breast	BCSdx	78.38%	81.20%	75.16%
	BCSRT	62.89%	60.80%	50.39%
	BneoCT	82.22%	95.71%	93.18%
Cervical	CBRR1	50.00%	66.67%	Data Not Available
Colon	ACT	86.36%	85.71%	88.89%
	C12RLN	92.42%	85.14%	98.39%
Gastric	G16RLN	85.71%	100.00%	75.00%


Notifications (Click on Notifications link on the left navigation bar)

Date	Notification
1/13/2025	ACS and IQVIA Martin Luther King Jr Holiday Office...
1/8/2025	RCRS Maintenance Saturday, 1/11 12:00 AM to 5:0...
1/7/2025	Updated CQIP 2024 Report released January 2, 2025

Go To Reports


Alert Summary

Note: report displays data available for the latest 3 years.



Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Home Page

Currently Viewing

National Cancer Database
20000690 Riverside Health System –
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Dashboard

CoC Quality Measures

Note: report displays data available for the current year - 2, as well as 2 years of subsequent data.

Primary Site	Measure	2021 PR	2022 PR	2023 PR
Bladder	BLCT1	43.75%	42.86%	30.00%
	BCSdx	78.38%	81.20%	75.16%
Breast	BCSRT	62.89%	60.80%	50.39%
	BneoCT	82.22%	95.71%	93.18%
	CBRRT	50.00%	66.67%	Data Not Available
Colon	ACT	86.36%	85.71%	88.89%
	C12RLN	92.42%	85.14%	98.39%
Gastric	G16RLN	85.71%	100.00%	75.00%


Notifications (Click on Notifications link on the left navigation bar)

Date	Notification
1/13/2025	ACS and IQVIA Martin Luther King Jr Holiday Office...
1/8/2025	RCRS Maintenance Saturday, 1/11 12:00 AM to 5:0...
1/7/2025	Updated CQIP 2024 Report released January 2, 2025

Go To Reports


Alert Summary

Note: report displays data available for the latest 3 years.



Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Home Page

Currently Viewing

National Cancer Database
20000690 Riverside Health System –
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Dashboard

CoC Quality Measures

Note: report displays data available for the current year - 2, as well as 2 years of subsequent data.

Primary Site	Measure	2021 PR	2022 PR	2023 PR
Bladder	BLCT1	43.75%	42.86%	30.00%
	BCSdx	78.38%	81.20%	75.16%
Breast	BCSRT	62.89%	60.80%	50.39%
	BneoCT	82.22%	95.71%	93.18%
	CBRRT	50.00%	66.67%	Data Not Available
Colon	ACT	86.36%	85.71%	88.89%
	C12RLN	92.42%	85.14%	98.39%
Gastric	G16RLN	85.71%	100.00%	75.00%


Notifications (Click on Notifications link on the left navigation bar)

Date	Notification
1/13/2025	ACS and IQVIA Martin Luther King Jr Holiday Office...
1/8/2025	RCRS Maintenance Saturday, 1/11 12:00 AM to 5:0...
1/7/2025	Updated CQIP 2024 Report released January 2, 2025

Go To Reports


Alert Summary

Note: report displays data available for the latest 3 years.



Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Home Page

Currently Viewing

National Cancer Database
20000690 Riverside Health System –
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account


Log out

Dashboard

CoC Quality Measures


Note: report displays data available for the current year - 2, as well as 2 years of subsequent data.

Primary Site	Measure	2021 PR	2022 PR	2023 PR
Bladder	BLCT1	43.75%	42.86%	30.00%
	BCSdx	78.38%	81.20%	75.16%
Breast	BCSRT	62.89%	60.80%	50.39%
	BneoCT	82.22%	95.71%	93.18%
	CBRRT	50.00%	66.67%	Data Not Available
Colon	ACT	86.36%	85.71%	88.89%
Gastric	C12RLN	92.42%	85.14%	98.39%
	G16RLN	85.71%	100.00%	75.00%




Alert Summary

Note: report displays data available for the latest 3 years.






Go To Reports



Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Home Page

Currently Viewing

National Cancer Database
20000690 Riverside Health System --
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out




Dashboard

[Go To Reports](#)

Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Currently Viewing

National Cancer Database
20000690 Riverside Health System –
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Home Page

Dashboard

CoC Quality Measures

Note: report displays data available for the current year - 2, as well as 2 years of subsequent data.

Primary Site	Measure	2021 PR	2022 PR	2023 PR
Bladder	BLCT1	43.75%	42.86%	30.00%
	BCSdx	78.38%	81.20%	75.16%
Breast	BCSRT	62.89%	60.80%	50.39%
	BneoCT	82.22%	95.71%	93.18%
Cervical	CBRR1	50.00%	66.67%	Data Not Available
Colon	ACT	86.36%	85.71%	88.89%
	C12RLN	92.42%	85.14%	98.39%
Gastric	G16RLN	85.71%	100.00%	75.00%

Notifications (Click on Notifications link on the left navigation bar)

Date	Notification
1/13/2025	ACS and IQVIA Martin Luther King Jr Holiday Office...
1/8/2025	RCRS Maintenance Saturday, 1/11 12:00 AM to 5:0...
1/7/2025	Updated CQIP 2024 Report released January 2, 2025



[Go To Reports](#)


Alert Summary

Note: report displays data available for the latest 3 years.



Quality Measures Comparison (DX Year: 2024)

Note: report displays data available for the current year - 1.





Welcome,
Aaron Bleznak

Currently Viewing

National Cancer Database
20000690 Riverside Health System --
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Operational Reports

Cancer Reports

Alerts Report

This report provides an overview as well as detailed information regarding cases with outstanding alerts and the associated edit errors.

Note: report displays data available for the latest 3 years.

Case Log Report

This report allows users to view a filtered list of cases, along with case-level edits.

Note: report displays data available for the latest 6 years.

Quality Measures Report

This report provides details for all quality measures.

Note: report displays data available for the latest 5 years.

Comparisons Report

This report allows users to view different performance rates for quality measures and compare the rates from the users' program to the users' program category to all CoC programs.

Note: report displays data available for the latest 6 years.

Completeness Report

The purpose of this report is to give CoC accredited programs information about required data items for which they may not be providing all of the information that is available in the patient record.

Submission Compliance Report

This report allows users to track their annual submission compliance using the 90% rule, by viewing the total cases free from NCDB edits submitted before and after December 31st of the year following the diagnosis.

Note: Report displays data available for the last 6 years.



Quality Measures Report - 20000690 Riverside Health System

File

Collapse/Expand Clear Selection

Run Date/Time: 01/21/2025 07:48:33 PM EST

Report Description



This report provides details for all quality measures. Note: report displays data available for the latest 5 years.

Notice: Data and Reports are STRICTLY CONFIDENTIAL. Use of these data and reports is restricted solely to each participating medical center FOR INTERNAL QUALITY IMPROVEMENT AND PEER REVIEW PURPOSES ONLY. Any other use of the data is prohibited unless approved by the ACS.

Summary Panel

Filters

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2024 Estimated Performance Rate	2023 Performance Rate	2022 Performance Rate	2021 Performance Rate
Bladder	BLCT1	For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy is initiated within 24 hours of the procedure, or recommended	PR/EPR 95% CI Benchmark	38.89%	36.84% [15.15% - 58.53%] 0%	30.00% [9.92% - 50.08%] 0%	42.86% [21.69% - 64.02%] 0%	43.75% [19.44% - 68.06%] 0%
Breast	BCSdx	For patients with AJCC Clinical Stage I-III breast cancer, the first therapeutic surgery in a non-neoadjuvant setting is performed within and including 60 days of diagnosis	PR/EPR 95% CI Benchmark	80.60%	80.33% [73.27% - 87.38%] 0%	75.16% [68.40% - 81.92%] 0%	81.20% [74.12% - 88.28%] 0%	78.38% [70.72% - 86.04%] 0%
	BCSRT	For patients undergoing breast-conserving surgery without adjuvant chemo or immunotherapy for stage I-III breast cancer, radiation therapy, when administered, is initiated <= 60 days of definitive surgery	PR/EPR 95% CI Benchmark	50.00%	48.10% [37.08% - 59.12%] 0%	50.39% [41.70% - 59.09%] 0%	60.80% [52.24% - 69.36%] 0%	62.89% [53.27% - 72.50%] 0%
	BneoCT	For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	86.67% [69.46% - 100.00%] 0%	93.18% [85.73% - 100.00%] 0%	95.71% [90.97% - 100.00%] 0%	82.22% [71.05% - 93.39%] 0%
Cervical	CBRRT	For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used	PR/EPR 95% CI Benchmark	100.00%	50.00% [0.00% - 100.00%] 0%	* Data Not Available	66.67% [13.32% - 100.00%] 0%	50.00% [9.99% - 90.01%] 0%
Colon	ACT	For patients under the age of 80 with surgically-managed pathologic stage III colon cancer (N>0), adjuvant chemotherapy is initiated within 4 months (120 days) of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	100.00% [100.00% - 100.00%] 0%	88.89% [77.03% - 100.00%] 0%	85.71% [72.75% - 98.68%] 0%	86.36% [72.02% - 100.00%] 0%



Measure Eligibility by Case Count

Select cell(s) from Quality Measures to view the Case Detail

Case List

Select bar(s) from Case Details to view the Case List.

Quality Measures Report - 20000690 Riverside Health System

File
Collapse/Expand Clear Selection

Run Date/Time: 01/21/2025 07:48:33 PM EST

Report Description

This report provides details for all quality measures. Note: report displays data available for the latest 5 years.

Notice: Data and Reports are STRICTLY CONFIDENTIAL. Use of these data and reports is restricted solely to each participating medical center FOR INTERNAL QUALITY IMPROVEMENT AND PEER REVIEW PURPOSES ONLY. Any other use of the data is prohibited unless approved by the ACS.

Summary Panel

Filters

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2024 Estimated Performance Rate	2023 Performance Rate	2022 Performance Rate	2021 Performance Rate
Bladder	BLCT1	For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy is initiated within 24 hours of the procedure, or recommended	PR/EPR 95% CI Benchmark	38.89%	36.84% [15.15% - 58.53%] 0%	30.00% [9.92% - 50.08%] 0%	42.86% [21.70% - 64.02%] 0%	43.75% [19.44% - 68.06%] 0%
Breast	BCSdx	For patients with AJCC Clinical Stage I-III breast cancer, the first therapeutic surgery in a non-neoadjuvant setting is performed within and including 60 days of diagnosis	PR/EPR 95% CI Benchmark	80.60%	80.33% [73.27% - 87.38%] 0%	75.16% [68.40% - 81.92%] 0%	74.00% [74.12% - 88.28%] 0%	78.38% [70.72% - 86.04%] 0%
	BCSRT	For patients undergoing breast-conserving surgery without adjuvant chemo or immunotherapy for stage I-III breast cancer, radiation therapy, when administered, is initiated <= 60 days of definitive surgery	PR/EPR 95% CI Benchmark	50.00%	48.10% [37.08% - 59.12%] 0%	50.39% [41.70% - 59.09%] 0%	60.80% [52.24% - 69.36%] 0%	62.89% [53.27% - 72.50%] 0%
	BneoCT	For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	86.67% [69.46% - 100.00%] 0%	93.18% [85.73% - 100.00%] 0%	95.71% [90.97% - 100.00%] 0%	82.22% [71.05% - 93.39%] 0%
Cervical	CBRRT	For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used	PR/EPR 95% CI Benchmark	100.00%	50.00% [0.00% - 100.00%] 0%	* Data Not Available	66.67% [13.32% - 100.00%] 0%	50.00% [9.99% - 90.01%] 0%
Colon	ACT	For patients under the age of 80 with surgically-managed pathologic stage III colon cancer (N>0), adjuvant chemotherapy is initiated within 4 months (120 days) of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	100.00% [100.00% - 100.00%] 0%	88.89% [77.03% - 100.00%] 0%	85.71% [72.75% - 98.68%] 0%	86.36% [72.02% - 100.00%] 0%

Measure Eligibility by Case Count

Category	Count
Denominator	157
Numerator	118
Non-Concordant	39
Incomplete	14
Not Eligible	513
Total Cases	684

Case List

Select bar(s) from Case Details to view the Case List.

Quality Measures Report - 20000690 Riverside Health System

File

Collapse/Expand Clear Selection

Run Date/Time: 01/21/2025 07:48:33 PM EST

Report Description


This report provides details for all quality measures.
Note: report displays data available for the latest 5 years.

Notice: Data and Reports are STRICTLY CONFIDENTIAL. Use of these data and reports is restricted solely to each participating medical center FOR INTERNAL QUALITY IMPROVEMENT AND PEER REVIEW PURPOSES ONLY. Any other use of the data is prohibited unless approved by the ACS.

Summary Panel


Filters

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2024 Estimated Performance Rate	2023 Performance Rate	2022 Performance Rate	2021 Performance Rate
Bladder	BLCT1	For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy is initiated within 24 hours of the procedure, or recommended	PR/EPR 95% CI Benchmark	38.89%	36.84% [15.15% - 58.53%] 0%	30.00% [9.92% - 50.08%] 0%	42.86% [21.69% - 64.02%] 0%	43.75% [19.44% - 68.06%] 0%
Breast	BCSdx	For patients with AJCC Clinical Stage I-III breast cancer, the first therapeutic surgery in a non-neoadjuvant setting is performed within and including 60 days of diagnosis	PR/EPR 95% CI Benchmark	80.60%	80.33% [73.27% - 87.38%] 0%	75.16% [68.40% - 81.92%] 0%	81.20% [74.12% - 88.28%] 0%	78.38% [70.72% - 86.04%] 0%
	BCSRT	For patients undergoing breast-conserving surgery without adjuvant chemo or immunotherapy for stage I-III breast cancer, radiation therapy, when administered, is initiated <= 60 days of definitive surgery	PR/EPR 95% CI Benchmark	50.00%	48.10% [37.08% - 59.12%] 0%	50.39% [41.70% - 59.09%] 0%	60.80% [52.24% - 69.36%] 0%	62.89% [53.27% - 72.50%] 0%
	BneoCT	For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	86.67% [69.46% - 100.00%] 0%	93.18% [85.73% - 100.00%] 0%	95.71% [90.97% - 100.00%] 0%	82.22% [71.05% - 93.39%] 0%
Cervical	CBRRT	For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used	PR/EPR 95% CI Benchmark	100.00%	50.00% [0.00% - 100.00%] 0%	* Data Not Available	66.67% [13.32% - 100.00%] 0%	50.00% [9.99% - 90.01%] 0%
Colon	ACT	For patients under the age of 80 with surgically-managed pathologic stage III colon cancer (N>0), adjuvant chemotherapy is initiated within 4 months (120 days) of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	100.00% [100.00% - 100.00%] 0%	88.89% [77.03% - 100.00%] 0%	85.71% [72.75% - 98.68%] 0%	86.36% [72.02% - 100.00%] 0%



Case List

FIN	Facility Name	Acc#	Seq#	DX Year	Primary Site	Measure
8340520	Riverside Regiona...	200500903	02	2023	Breast	BCSdx
8340520	Riverside Regiona...	202300480	00	2023	Breast	BCSdx
8340520	Riverside Regiona...	202100408	02	2023	Breast	BCSdx
8340520	Riverside Regiona...	202301836	00	2023	Breast	BCSdx
8340520	Riverside Regiona...	202302209	00	2023	Breast	BCSdx
8340520	Riverside Regiona...	202300258	00	2023	Breast	BCSdx
8340520	Riverside Regiona...	202300411	00	2023	Breast	BCSdx
8340520	Riverside Regiona...	202301801	00	2023	Breast	BCSdx



Quality Measures Report - 20000690 Riverside Health System

Report Description

Summary Panel

Summary View: Table

Measure Group: All Measure Groups

Disease Site:

- (All)
- Bladder
- Breast
- Cervical
- Colon
- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

- (All) 6 values
- 2025
- 2024
- 2023
- 2022
- 2021
- Rolling Year EPR

Quality Measures

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2024 Estimated Performance Rate	2023 Performance Rate	2022 Performance Rate	2021 Performance Rate
Bladder	BLCT1	For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy is initiated within 24 hours of the procedure, or recommended	PR/EPR 95% CI Benchmark	38.89%	36.84% [15.15% - 58.53%] 0%	30.00% [9.92% - 50.08%] 0%	42.86% [21.69% - 64.02%] 0%	43.75% [19.44% - 68.06%] 0%
Breast	BCSdx	For patients with AJCC Clinical Stage I-III breast cancer, the first therapeutic surgery in a non-neoadjuvant setting is performed within and including 60 days of diagnosis	PR/EPR 95% CI Benchmark	80.60%	80.33% [73.27% - 87.38%] 0%	75.16% [68.40% - 81.92%] 0%	81.20% [74.12% - 88.28%] 0%	78.38% [70.72% - 86.04%] 0%
	BCSRT	For patients undergoing breast-conserving surgery without adjuvant chemo or immunotherapy for stage I-III breast cancer, radiation therapy, when administered, is initiated <= 60 days of definitive surgery	PR/EPR 95% CI Benchmark	50.00%	48.10% [37.08% - 59.12%] 0%	50.39% [41.70% - 59.09%] 0%	60.80% [52.24% - 69.36%] 0%	62.89% [53.27% - 72.50%] 0%
	BneoCT	For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	86.67% [69.46% - 100.00%] 0%	93.18% [85.73% - 100.00%] 0%	95.71% [90.97% - 100.00%] 0%	82.22% [71.05% - 93.39%] 0%
Cervical	CBRRT	For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used	PR/EPR 95% CI Benchmark	100.00%	50.00% [0.00% - 100.00%] 0%	* Data Not Available	66.67% [13.32% - 100.00%] 0%	50.00% [9.99% - 90.01%] 0%
Colon	ACT	For patients under the age of 80 with surgically-managed pathologic stage III colon cancer (N>0), adjuvant chemotherapy is initiated within 4 months (120 days) of diagnosis, or recommended	PR/EPR 95% CI Benchmark	89.47%	100.00% [100.00% - 100.00%] 0%	88.89% [77.03% - 100.00%] 0%	85.71% [72.75% - 98.68%] 0%	86.36% [72.02% - 100.00%] 0%

Measure Eligibility by Case Count

Denominator	157
Numerator	118
Non-Concordant	39
Incomplete	14
Not Eligible	513
Total Cases	684

Case List

FIN	Facility Name	Acc#	Seq#	DX Year	Primary Site	Measure
6340520	Riverside Regiona...	200500903	02	2023	Breast	BCSdx
6340520	Riverside Regiona...	202300480	00	2023	Breast	BCSdx
6340520	Riverside Regiona...	202100408	02	2023	Breast	BCSdx
6340520	Riverside Regiona...	202301836	00	2023	Breast	BCSdx
6340520	Riverside Regiona...	202302209	00	2023	Breast	BCSdx
6340520	Riverside Regiona...	202300258	00	2023	Breast	BCSdx
6340520	Riverside Regiona...	202300411	00	2023	Breast	BCSdx
6340520	Riverside Regiona...	202301801	00	2023	Breast	BCSdx

Quality Measure

Report Description

Summary Panel

Summary View: **Table**

Measure Group: **Trend**

Disease Site:

- (All)
- Bladder
- Breast
- Cervical
- Colon
- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

- (All) 6 values
- 2025
- 2024
- 2023
- 2022
- 2021
- Rolling Year EPR

Facilities: **20000690**

Report Description

Summary Panel

Summary View: **Table**

Measure Group: **All Measure Groups**

Disease Site:

- (All)
- Bladder
- Breast
- Cervical
- Colon
- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:


Type to search in list

- (All) 6 values
- 2025
- 2024
- 2023
- 2022
- 2021
- Rolling Year EPR

PR	2024 Estimated Performance Rate	2023 Performance Rate	2022 Performance Rate	2021 Performance Rate
	36.84% [15.15% - 58.53%] 0%	30.00% [9.92% - 50.08%] 0%	42.86% [21.69% - 64.02%] 0%	43.75% [19.44% - 68.06%] 0%
	80.33% [73.27% - 87.38%] 0%	75.16% [68.40% - 81.92%] 0%	81.20% [74.12% - 88.28%] 0%	78.38% [70.72% - 86.04%] 0%
	48.10% [37.08% - 59.12%] 0%	50.39% [41.70% - 59.09%] 0%	60.80% [52.24% - 69.36%] 0%	62.89% [53.27% - 72.50%] 0%
	86.67% [69.46% - 100.00%] 0%	93.18% [85.73% - 100.00%] 0%	95.71% [90.97% - 100.00%] 0%	82.22% [71.05% - 93.39%] 0%
	50.00% [0.00% - 100.00%] 0%	* Data Not Available	66.67% [13.32% - 100.00%] 0%	50.00% [9.99% - 90.01%] 0%
	100.00% [100.00% - 100.00%] 0%	88.89% [77.03% - 100.00%] 0%	85.71% [72.75% - 98.68%] 0%	86.36% [72.02% - 100.00%] 0%

Facility Name	Acc#	Seq#	DX Year	Primary Site	Measure
Riverside Regiona...	200500903	02	2023	Breast	BCSdx
Riverside Regiona...	202300480	00	2023	Breast	BCSdx
Riverside Regiona...	202100408	02	2023	Breast	BCSdx
Riverside Regiona...	202301836	00	2023	Breast	BCSdx
Riverside Regiona...	202302209	00	2023	Breast	BCSdx
Riverside Regiona...	202300258	00	2023	Breast	BCSdx
Riverside Regiona...	202300411	00	2023	Breast	BCSdx
Riverside Regiona...	202301801	00	2023	Breast	BCSdx

Quality Measures Report - 20000690 Riverside Health System



Summary Panel

Summary View: Bar Chart

Measure Group: All Measure Groups

Disease Site:



- (All)
- Bladder
- Breast
 - BCSdx
 - BCSRT
 - BneoCT
- Cervical
- Colon
- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

(All) 6 values

- 2025
- 2024
- 2023
- 2022
- 2021
- Rolling Year EPR



Case List

FIN	Facility Name	Acc#	Seq#	DX Year	Primary Site	Measure
8340821	Riverside Walter R...	202300394	00	2023	Breast	BCSRT
8340820	Riverside Regiona...	202300079	00	2023	Breast	BCSRT
8340820	Riverside Regiona...	202301211	00	2023	Breast	BCSRT
8340820	Riverside Regiona...	202302197	00	2023	Breast	BCSRT
8340821	Riverside Walter R...	202300316	00	2023	Breast	BCSRT
8340821	Riverside Walter R...	202300183	00	2023	Breast	BCSRT
8340820	Riverside Regiona...	202400030	00	2023	Breast	BCSRT
8340820	Riverside Regiona...	202301330	00	2023	Breast	BCSRT

Welcome,
Aaron Bleznak

Currently Viewing

National Cancer Database
20000690 Riverside Health System --
NT18470

Switch Current View

DASHBOARD

Home Page

PLATFORM

Notifications 77

ANALYTICS

Operational Reports

RESOURCES

Library

QPORT

ACCOUNT

My Account

Log out

Operational Reports

Cancer Reports

Alerts Report

This report provides an overview as well as detailed information regarding ca
Note: report displays data available for the latest 3 years.

Case Log Report

This report allows users to view a filtered list of cases, along with case-level
Note: report displays data available for the latest 6 years.

Quality Measures Report

This report provides details for all quality measures.
Note: report displays data available for the latest 5 years.

Comparisons Report

This report allows users to view different performance rates for quality meas
Note: report displays data available for the latest 6 years.

Completeness Report

The purpose of this report is to give CoC accredited programs information at

Submission Compliance Report

This report allows users to track their annual submission compliance using th
Note: Report displays data available for the last 6 years.

Time Period: Annually

Measure:

- Bladder
- Breast
- Cervical
- Colon
- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

- (All) 5 values
- 2020
- 2021
- 2022
- 2023
- 2024

Comparison Group:

- My Facility (20000690)
- My Facility (6340500)
- My Facility (6340520)
- My Facility (6340521)
- ACS Division(Southeast)
- All CoC Programs
- Census Region(South Atlantic)
- Program Category(INCP)
- State(VA)

program category to all CoC programs.

the information that is available in the patient record.

mitted before and after December 31st of the year following the diagnosis.



Comparisons Report - 20000690 Riverside Health System

File

- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

- (All) 5 values
- 2020
- 2021
- 2022
- 2023
- 2024

Comparison Group:

- My Facility (20000690)
- My Facility (6340500)
- My Facility (6340520)
- My Facility (6340521)
- ACS Division(Southeast)
- All CoC Programs
- Census Region(South Atlantic)
- Program Category(INCP)
- State(VA)

Filters

Performance Rate Comparisons

Program Category	Year	PR/EPR (%)
My Facility (6340520)	2023	~68
	2024	~78
	2023	~53
	2024	~46
Program Category(INCP)	2023	~73
	2024	~78
	2023	~65
	2024	~68

Performance Rate By - Age at Diagnosis

Select data from the Performance Rate Comparison to view the Performance Rate Comparison By.

PR/EPR (%)

Details with Case Counts By Age

Select data from the Performance Rate By to view the Details with Case Counts By.

Comparisons Report - 20000690 Riverside Health System

File

- Gastric
- HeadNeck
- Kidney
- Lung
- Melanoma
- Prostate
- Rectum

Diagnosis Year:

Type to search in list

(All) 6 values

- 2020
- 2021
- 2022
- 2023
- 2024
- 2025

Comparison Group:

- My Facility (20000690)
- My Facility (6340500)
- My Facility (6340520)
- My Facility (6340521)
- ACS Division(Southeast)
- All CoC Programs
- Census Region(South Atlantic)
- Program Category(INCP)
- State(VA)

Filters

Performance Rate Comparisons

Legend: My Facility (6340520) (Red), All CoC Programs (Purple), Program Category (Green)

Performance Rate By - Age at Diagnosis

Details with Case Counts By Age

Age at Diagnosis	BC Sdx		
	My Facility (6340520)		
	PR/EPR (%)	Distinct_Cases	CI (%)
50 TO 59	69.23%	107	51.49%-88.97%
60 TO 69	77.78%	165	64.20%-91.38%
70 TO 79	66.87%	103	48.50%-88.83%
80 AND OVER	73.88%	49	53.88%-93.48%

Comparisons Report - 20000690 Riverside Health System

Run Date/Time: 01/22/2025 05:11:57 PM EST
 Clear Selection | Reset Zoom | Collapse/Expand



Report Description

Summary Panel

Filters

Graph Comparisons As:
 Bar Chart

Stratification: Race



Details with Case Counts By Race

Race	BCSdx		
	My Facility (20000690)		
	PR/EPR (%)	Distinct_Cases	CI (%)
White	77.27%	394	68.52%-88.03%
Black	67.86%	158	51.92%-83.37%
Hispanic	100.00%	13	100.00%-100.00%
API	100.00%	9	100.00%-100.00%
Other/Unknown	75.00%	110	60.00%-90.00%

USER TIP SHEET

HCBM Navigation
HCBM TipSheet
HCBM Graphs

HOSPITAL SELECTION

Hosp. Type / System
Geographic Areas

CASE SELECTION

About Case Selection

ANALYSIS VARIABLES

Patient Demograph.
First Crs. Therapy
Days to 1st Rx.
Tumor Charact.

TERMS AND CONDITIONS

NCDB Public
Reporting Policy



AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

NCDB

BENCHMARK REPORTS

NCDB Hospital Comparison Benchmark Reports. Cases Diagnosed 2013 - 2022.

My Hospital Only Aggregate Report Comparison Report

Submit

- Riverside Health System, Newport News VA
- Riverside Regional Medical Center, Newport News VA
- Riverside Shore Memorial Hospital, Onancock VA
- Riverside Walter Reed Hospital, Gloucester VA
- University of Texas Medical Branch Hospitals, Galveston TX

Dx. Year Deselect All 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Site Breast

Case Type All Diagnosis Types

Analysis Variables

Var. 1 Age Group **Var. 2** - not selected - **Var. 3** - not selected -

- Review the appropriate "Terms & Conditions" Agreement in advance of using any text, tables or figures generated from the NCDB Benchmark Reports
- Use of these data and the NCDB Hospital Comparison Benchmarks is strictly limited to registered CoC Datalinks users for this CoC-Accredited Cancer Program only and should not be shared with unauthorized users at any other facility. The CoC is not responsible for the unauthorized release or sharing of data by any user.
- For technical assistance - contact ncdb@facs.org

Submit

USER TIP SHEET

HCBM Navigation
HCBM TipSheet
HCBM Graphs

**HOSPITAL
SELECTION**

Hosp. Type / System
Geographic Areas

**CASE
SELECTION**

About Case Selection

**ANALYSIS
VARIABLES**

Patient Demograph.
First Crs. Therapy
Days to 1st Rct.
Tumor Charact.

**TERMS AND
CONDITIONS**

NCDB Public
Reporting Policy



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:
Highest Standards, Better Outcomes

NCDB

BENCHMARK REPORTS

NCDB Hospital Comparison Benchmark Reports. Cases Diagnosed 2013 - 2022.

My Hospital Only Aggregate Report Comparison Report

Submit

- Riverside Health System, Newport News VA
- Riverside Regional Medical Center, Newport News VA
- Riverside Shore Memorial Hospital, Onancock VA
- Riverside Walter Reed Hospital, Gloucester VA
- University of Texas Medical Branch Hospitals, Galveston TX

Dx. Year Deselect All 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Site Breast

Case Type Combination: Class of Case 00 and Class of Case 10-14

Analysis Variables

Var. 1 **Var. 2** **Var. 3**

Diagnosis Year Stage - not selected -

- Review the appropriate "Terms & Conditions" Agreement in advance of using any text, tables or figures generated from the NCDB Benchmark Reports
- Use of these data and the NCDB Hospital Comparison Benchmarks is strictly limited to registered CoC Datalinks users for this CoC-Accredited Cancer Program only and should not be shared with unauthorized users at any other facility. The CoC is not responsible for the unauthorized release or sharing of data by any user.
- For technical assistance - contact ncdb@facs.org


Submit



Chart N % Img Custom Table N %

Trouble viewing charts or need help? Check our [FAQ](#) or contact: ncdb@facs.org

Riverside Regional Medical Center, Newport News, VA 23601
Diagnosis Year by Stage of Breast Cancer Diagnosed in 2013 to 2022
Combination: Class of Case 00 and Class of Case 10-14



0 I II III IV NA UNK

Riverside Regional Medical Center, Newport News, VA 23601
Diagnosis Year by Stage of Breast Cancer Diagnosed in 2013 to 2022
Combination: Class of Case 00 and Class of Case 10-14

Diagnosis Year	Stage							Totals	
	0	I	II	III	IV	NA	UNK	N	%
1 2013	22	72	39	15	8	0	2	158	8.7%
	13.9%	45.6%	24.7%	9.5%	5.1%	0	1.3%	100%	
2 2014	29	67	51	22	14	0	1	184	10.13%
	15.8%	36.4%	27.7%	12%	7.6%	0	0.5%	100%	
3 2015	32	65	39	17	5	0	3	161	8.87%
	19.9%	40.4%	24.2%	10.6%	3.1%	0	1.9%	100%	
4 2016	34	75	50	12	8	0	2	181	9.97%
	18.8%	41.4%	27.6%	6.6%	4.4%	0	1.1%	100%	
5 2017	37	76	48	18	8	0	0	187	10.3%
	19.8%	40.6%	25.7%	9.6%	4.3%	0	0	100%	
6 2018	24	78	30	12	9	3	3	159	8.76%
	15.1%	49.1%	18.9%	7.5%	5.7%	1.9%	1.9%	100%	
7 2019	18	95	27	11	8	3	15	177	9.75%
	10.2%	53.7%	15.3%	6.2%	4.5%	1.7%	8.5%	100%	
8 2020	14	119	22	14	13	4	15	201	11.07%
	7%	59.2%	10.9%	7%	6.5%	2%	7.5%	100%	
9 2021	26	117	23	14	8	1	10	199	10.96%
	13.1%	58.8%	11.6%	7%	4%	0.5%	5%	100%	
10 2022	27	126	30	11	10	1	4	209	11.51%
	12.9%	60.3%	14.4%	5.3%	4.8%	0.5%	1.9%	100%	
TOTAL	263	890	359	146	91	12	55	1816	100%
	14.5%	49%	19.8%	8%	5%	0.7%	3%	100%	

USER TIP SHEET

HCBM Navigation
HCBM TipSheet
HCBM Graphs

HOSPITAL SELECTION

Hosp. Type / System
Geographic Areas

CASE SELECTION

About Case Selection

ANALYSIS VARIABLES

Patient Demograph.
First Crs. Therapy
Days to 1st Rx.
Tumor Charact.

TERMS AND CONDITIONS

NCDB Public
Reporting Policy



AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

NCDB

BENCHMARK REPORTS



NCDB Hospital Comparison Benchmark Reports. Cases Diagnosed 2013 - 2022.

My Hospital Only **Aggregate Report** **Comparison Report**

Submit

- Riverside Health System, Newport News VA
- Riverside Regional Medical Center, Newport News VA
- Riverside Shore Memorial Hospital, Onancock VA
- Riverside Walter Reed Hospital, Gloucester VA
- University of Texas Medical Branch Hospitals, Galveston TX

Dx. Year Select All 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Site Breast

Case Type Combination: Class of Case 10-14 and Class of Case 20-22

Analysis Variables

Var. 1 First Course Surgery

Hosp. Type: All Types

Geo: State Virginia

- Review the appropriate "Terms & Conditions" Agreement in advance of using any text, tables or figures generated from the NCDB Benchmark Reports
- Use of these data and the NCDB Hospital Comparison Benchmarks is strictly limited to registered CoC Datalinks users for this CoC-Accredited Cancer Program only and should not be shared with unauthorized users at any other facility. The CoC is not responsible for the unauthorized release or sharing of data by any user.
- For technical assistance - contact ncdb@facs.org

Submit



Chart
 N
 %
 Img
 Top 5 Custom
 Table
 Top 10 Save as
 [PDF](#)
 [Power Point](#)
 [HOME](#)

Viewing charts or need help? Check our [FAQ](#) or contact: nodb@facs.org

First Course Surgery of Breast Cancer Diagnosed in 2020,2021,2022
 Riverside Regional Medical Center, Newport News VA
 vs. All Types Hospitals in State of Virginia
 Combination: Class of Case 10-14 and Class of Case 20-22 - Data from 44 Hospitals







Chart N % Img Custom Table N % Save as PDF Power Point HOME

Trouble viewing charts or need help? Check our [FAQ](#) or contact: ncdb@facs.org

Riverside Regional Medical Center, Newport News, VA 23601
Race/Ethnicity by Stage of Breast Cancer Diagnosed in 2020,2021,2022
Combination: Class of Case 00 and Class of Case 10-14



Open Forum





Thank you!

Questions?

Melissa Leeb: mleeb@facs.org

Rebecca Medina: rmedina@facs.org



facs.org/quality-programs/cancer-programs/



ACS Cancer Programs



@AmColSurgCancer